A systematic review published in The BMJ on May 20, 2026 pooled 69 randomized controlled trials involving 153,902 adults and found that calcium and vitamin D supplements offer little to no clinically meaningful protection against fractures or falls in most older people. Its lead authors are Olivier Massé of Sacred Heart Hospital of Montreal and Guylène Thériault of the University of Montreal. The findings, they wrote, “do not support routine supplementation with calcium, vitamin D or combined supplementation to prevent fractures or falls.”
The paper is now four months old and resurfaced on aggregator sites on September 20. Its bottom line has not changed, and neither has the objection to it, which comes from the bone-health specialists who treat the patients the trials left out.
Three supplement arms, and how strong the evidence was
The BMJ Group’s release says the Canadian team compared supplements against placebo and graded the evidence for each. For vitamin D alone, certainty was high, drawn from 36 trials with 92,045 participants. For combined calcium and vitamin D it was also high, from 15 trials with 51,126 participants. For calcium alone it was moderate, from 11 trials with 9,067 participants.
The grade matters because a null result from a weak evidence base is easy to dismiss. Here the two biggest arms are the ones judged most reliable, with 92,045 and 51,126 participants respectively, so the weight of the conclusion rests on the strongest evidence rating rather than on the thinnest one. Calcium alone, at 9,067 participants, is the smallest and least certain arm, and the review’s conclusion about it is the one most open to revision by a future large trial.
Results held across subgroups by age, sex, prior fracture and dietary intake, according to the release. The Healio report of June 2 adds the one place where a statistical signal appeared: combined supplementation lowered relative risk to 0.91 for any fracture, 0.84 for hip fracture and 0.92 for falls. Those reductions “did not meet the study’s criteria for clinically meaningful benefit,” the review’s authors concluded, so a real but small effect was not counted as a useful one.
Where the evidence stops applying
The review excluded people with osteoporosis and those taking anti-osteoporosis drugs, and its authors said such patients “may have different needs and should not assume the findings apply directly to them.” That limit is the ground on which the strongest rebuttal was built.
On July 3, Osteoporosis Canada’s rapid response team, whose named authors include Marie-Josée Bégin, Claudia Gagnon and Laetitia Michou, published a position statement disputing the conclusion that supplementation has no clinical benefit. Its reading of the same numbers was that “these results remain significant and could support interventions aimed at preventing fractures, including serious events such as hip fractures,” and that the findings are “not generalizable to people living with osteoporosis or on anti-osteoporosis treatment.”
The two positions are less far apart on practice than on framing. Osteoporosis Canada, aligning with Health Canada, advises no calcium supplement when dietary intake already meets 1,000 to 1,200 mg a day, and 400 IU of vitamin D daily for people 50 and older, with more for those at risk of deficiency. Its advice to patients was to consult a healthcare professional before changing habits, a line that sits comfortably beside the review’s own caution that people with bone disorders should not treat the findings as a verdict on their situation.
Recommended intakes and what worked in earlier trials
The review does not argue that the nutrients are unimportant. The U.S. National Institutes of Health’s vitamin D fact sheet lists a recommended dietary allowance of 600 IU (15 mcg) for ages 51 to 70 and 800 IU (20 mcg) above age 70, and says adults should meet those amounts from food and supplements if needed. It also cites the 2022 VITAL trial, in more than 25,000 generally healthy adults, which found that vitamin D supplementation did not lower the risk of total, hip or nonvertebral fractures compared with placebo.
The BMJ authors point instead to interventions with a better record: balance training and resistance exercise, and multicomponent programs combining exercise, hazard assessment or education tailored to individual risk. Their suggestion for future research was to concentrate on people at higher risk, such as those with documented vitamin D deficiency or prior fractures, rather than repeat trials in the general older population.
The ScienceDaily repost of September 20 carries no new analysis. The unresolved question is the one both sides agree on: whether supplements help the people the trials mostly left out, those already being treated for or at high risk of osteoporosis, and that would take trials designed for them.
This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.
More from Morning Overview
- Doctors warn a silent liver disease now affects one in three American adults
- Hackers are hijacking outdated home routers, and the FBI named the models to check
- Older Teslas are wearing out in ways early owners never saw coming
- Early electric-car owners are hitting battery and screen failures no one warned them about
